0.00Open0.00Pre Close0 Volume0 Open Interest30.00Strike Price0.00Turnover4687.20%IV-80.94%PremiumJul 19, 2024Expiry Date13.42Intrinsic Value100Multiplier-2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8435Delta0.0304Gamma1.19Leverage Ratio-24.7981Theta0.0000Rho-1.00Eff Leverage0.0004Vega
Grail Stock Discussion
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet